Teva Launches Generic Allegra “At Risk” Under Barr’s Exclusivity
Executive Summary
Barr could take a one-time charge this quarter for estimated liability related to Teva's "at risk" launch of generic Allegra under Barr's exclusivity
You may also be interested in...
Teva/Barr Get The Green Light To Continue Marketing Generic Allegra
A New Jersey federal judge denied Sanofi-Aventis' request for a preliminary injunction to stop Teva/Barr from marketing generic Allegra.
Barr Allegra approval
Barr receives first ANDA approval for generic equivalent to Sanofi-Aventis'Allegra 60 mg capsules July 13. Barr maintains it is the first to file an ANDA for fexofenadine and is therefore entitled to a 180-day exclusivity period. Barr remains in litigation with Sanofi in New Jersey district court over five Allegra patents; the firm says the case may go to trial in early 2006. Barr was approved by FDA to market Allegra-D (fexofenadine/pseudoephedrine) generics in April, but has not yet launched the product (1"The Pink Sheet" April 18, 2005, In Brief)...
Pfizer Obtains Preliminary Injunction Against Teva/Ranbaxy Accupril Generic
A preliminary injunction halting the sale of generic versions of Pfizer's Accupril (quinapril)may be a discouraging sign for generic companies considering "at risk" launches